HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wella responds to P&G offer

This article was originally published in The Rose Sheet

Executive Summary

Procter & Gamble's tender offer for Wella shares is "fair based on all relevant circumstances," Wella's executive board says in May 9 statement. However, the board did not recommend whether shareholders should accept or decline the offer. P&G tendered an offer to buy Wella ordinary shares for $105.7 (€1=$1.15) and preference shares for $74.4 in April (1"The Rose Sheet" May 5, 2003, p. 5). P&G has offered Wella CEO Heiner Gürtler responsibility for the cosmetics and fragrances business Cosmopolitan Cosmetics, the global responsibility for the professional hair care division within P&G and membership in P&G's Global Leadership Council, Wella adds...

You may also be interested in...

P&G Tender Offer Increase Adds $86 Mil. To Wella Price Tag

Procter & Gamble increased its offer for Wella preference shares $3.86 (€1=$1.10) to $71.76 per share in a tender offer launched April 28

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts